Supplementary Table 7. Sensitivity analysis on the effect modification by TBIL in participants without use of antihypertensive medication

Outcome	Group	N	n (%)	Adj. OR/cOR (95% CI)*	*P*	*P* for interaction
Presence of CSVD (Wardlaw)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	258 (20.2)	Ref.		0.033
	Hypertension	352	126 (35.8)	1.81 (1.37–2.39)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	129 (27.6)	Ref.		
	Hypertension	145	50 (34.5)	1.07 (0.69–1.67)	0.767	
Presence of CSVD (Rothwell)†	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276	391 (30.6)	Ref.		0.037
	Hypertension	352	171 (48.6)	1.79 (1.39–2.32)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468	171 (36.5)	Ref.		
	Hypertension	145	64 (44.1)	1.12 (0.74–1.70)	0.597	
Total CSVD burden (Wardlaw)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.059
	Hypertension	352		1.83 (1.39–2.41)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468		Ref.		
	Hypertension	145		1.20 (0.79–1.85)	0.395	
Modified total CSVD burden (Rothwell)‡	Participants with TBIL ≤17 μmol/L					
	No hypertension	1,276		Ref.		0.046
	Hypertension	352		1.82 (1.42–2.33)	<0.001	
	Participants with TBIL >17 μmol/L					
	No hypertension	468		Ref.		
	Hypertension	145		1.18 (0.79–1.75)	0.424	

Participants undergoing antihypertensive medication treatment were excluded. All models were adjusted for age, sex, body mass index, current smoking, current drinking, diabetes, dyslipidemia, antiplatelet medication, anticoagulant medication, alanine aminotransferase, and aspartate aminotransferase.
TBIL, total bilirubin; Adj., adjust; OR, odds ratio; cOR, common odds ratio; CI, confidence interval; CSVD, cerebral small vessel disease; Ref., reference.
*The association of hypertension with the presence of CSVD was evaluated using OR, while with CSVD burden was evaluated using cOR. The product term of the hypertension state and TBIL group was included in the model to assess the effect modification by TBIL; †Presence of CSVD was defined as total CSVD or modified total CSVD burden scores ≥1; ‡Total and modified total CSVD burdens were classified as grade 0 (total or modified total CSVD burden score 0), grade 1 (total or modified total CSVD burden score 1), grade 2 (total or modified total CSVD burden score 2–3), or grade 3 (total or modified total CSVD burden score ≥4).